Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 10.16 Exhibit 10.16
- 10.17 Exhibit 10.17
- 10.18 Exhibit 10.18
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- Download Excel data file
- View Excel data file
Associated filings
- 3 Jan 24 EFFECT Notice of effectiveness
- 27 Dec 23 POS AM Prospectus update (post-effective amendment)
- 10 Jun 21 EFFECT Notice of effectiveness
- 9 Jun 21 424B3 Prospectus supplement
- 7 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 May 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 30 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
22 Mar 21 S-4 Registration of securities issued in business combination transactions
PNT similar filings
- 7 Jun 21 Registration of securities issued in business combination transactions (amended)
- 25 May 21 Registration of securities issued in business combination transactions (amended)
- 30 Apr 21 Registration of securities issued in business combination transactions (amended)
- 22 Mar 21 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 99.1
CONSENT
I hereby consent to serve as a director of Therapeutics Acquisition Corp. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and any prospectus and/or proxy statement contained therein.
| By: | /s/ Neil Fleshner, M.D., MPH |
|
| Name: Neil Fleshner, M.D., MPH |
|
|
|
Date: March 22, 2021 |
|
|